SGLT2 inhibitor empagliflozin could be a new treatment for children with type 2 diabetes: lancet

Published Date: 04 Mar 2023

United States: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, with phase 3 clinical trials showing...

Read Full News

Latest News

India Warns Drugmakers Against Weight-Loss Drug Ads

India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could...

Digital Microsteps Help GLP-1 Users Adopt Healthy Behaviors

Digitally delivered behavior-change prompts plus short videos can boost GLP-1 users’ expectations to adopt healthy lifestyle behaviors.

From Open Surgery to AI in Kidney Stone Care

Miniaturized percutaneous techniques, flexible ureteroscopy, and outpatient protocols have shortened hospital stays and improved recovery, reshaping quality-of-life outcomes for patients.

Early Introduction of Tirzepatide Yields T2D Benefits

Two-year data from Eli Lilly’s SURPASS-EARLY trial show reduced A1c, body weight, and cardiovascular risk factors.

West Virginia Can Ban Medicaid Coverage for Gender-affirming Surgery, US Court Rules

A U.S. appeals court on Tuesday upheld West Virginia's ban on Medicaid coverage for gender-affirming surgeries, the latest victory for Republican-led states seeking to curb...

Eli Lilly to Invest $3 Billion in China

Eli Lilly plans to invest $3 billion in China, which ⁠will help build production capacity for its experimental type-2 diabetes and obesity treatment orforglipron.

Todays Updates

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Todays Updates

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Latest News

India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could...

Digitally delivered behavior-change prompts plus short videos can boost GLP-1 users’ expectations to adopt healthy lifestyle behaviors.

Miniaturized percutaneous techniques, flexible ureteroscopy, and outpatient protocols have shortened hospital stays and improved recovery, reshaping quality-of-life outcomes for patients.

Two-year data from Eli Lilly’s SURPASS-EARLY trial show reduced A1c, body weight, and cardiovascular risk factors.

A U.S. appeals court on Tuesday upheld West Virginia's ban on Medicaid coverage for gender-affirming surgeries, the latest victory for Republican-led states seeking to curb...

Eli Lilly plans to invest $3 billion in China, which ⁠will help build production capacity for its experimental type-2 diabetes and obesity treatment orforglipron.

News All Time

How Policy and New Drugs Reshaped Obesity Treatment

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use of antiobesity medications, while bariatric surgery rates remain stable.

Self-Insulin Dosing Leads to Control in Gestational Diabetes

In individuals with gestational diabetes, patient-led insulin titration is linked to faster glycemic control and a lower risk for macrosomia than clinician-led approaches.

Chemical Exposure Detected in Semen Linked to Sperm Quality

High-resolution mass spectrometry identifies 42 nonvolatile organic compounds in semen samples from healthy young men.

Some US Medical Schools to Teach Nutrition Under Government Deal

About a fourth of U.S. medical schools will expand their nutrition education offerings this autumn as part of a ⁠deal with the administration of President Donald Trump, said...

Roche, Zealand's Obesity Drug Shows Up to 10.7% Weight Loss in Mid-stage Trial

Roche said on Thursday its experimental obesity drug, which it is developing with Denmark's Zealand Pharma, helped patients ⁠lose up to 10.7% of their body weight in a...

China Approves Pfizer GLP-1 Drug for Weight Loss

China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in ⁠overweight or obese adults, the U.S. drugmaker said on Friday.

Autonomic Dysfunction: A Hidden Driver of Gastroparesis?

Multimodal physiologic testing in patients with chronic gastroduodenal symptoms reveals autonomic dysfunction and links it to delayed gastric emptying.

Tendon Rupture Risk Linked With GLP-1 Use in Obese Patients

5-year findings call for physicians to balance the benefits of the medication for weight loss with the rupture risks, particularly for tendons that do the heavy lifting.

FDA Extends Approval of PKU Drug to Include Adolescents

Previously only approved for adults, BioMarin’s pegvaliase-pqpz (PALYNZIQ) is now licensed for patients as young as 12 years.

GLP-1 Weight Loss Higher Among Women

Studies in a new meta-analysis show sex differences in average weight loss, but similar benefits across other sub-groups.

Parent Stress Emerges as Key Factor in Child Obesity

Adding a parental mindfulness intervention improved parenting and child food intake and obesity risk over nutrition and activity counseling alone.

Novel Cortisol Blockade Controls Hypertension in Cushing

Relacorilant, a selective glucocorticoid receptor modulator, provides sustained blood pressure control and metabolic benefits in patients with Cushing syndrome, according to a phase 3 trial.

Lilly Launches Employer-connect Platform to Broaden Weight-loss Drug Access

Eli Lilly said on Thursday it has rolled out a platform to help employers connect ⁠with organizations offering low-cost benefits and comprehensive obesity-care programs,...

Pharmacist-Led Model Lowers Treatment-Related Hypoglycemia

A collaborative intervention model involving a clinical pharmacist significantly reduces severe hypoglycemia risk without compromising glycemic control.

GLP-1 vs DPP-4 Meds: Which Is Better for Diabetes Control?

Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

Bariatric Surgery Rates Fall as GLP-1s Gain Popularity

The use of GLP 1s increased dramatically from 2018 to 2025 among patients eligible for metabolic and bariatric surgery in the US, whereas surgery rates declined notably.